Correction Notice to TRxADE HEALTH Press Release Reporting Second Quarter Revenue Growth of 73% and Q2 2022 Financial Results Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform TRxADE

Notice to TRxADE HEALTH Press Release

Reporting Second Quarter Revenue Growth of 73% and Q2 2022 Financial Results

Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform

HEALTH, INC. (NASDAQ:MEDS) announced today that its press release issued under the headline "TRxADE HEALTH Reports Second Quarter

Revenue Growth of 73% and Q2 2022 Financial Results" on July 25, 2022, included errors in the disclosure of depreciation and amortization

for both the three and six months ended June 30, 2022, in the table entitled "Reconciliation of Net Income (Loss) attributable

to TRxADE HEALTH, INC., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA". A corrected

form of that table is included at the end of this release and the prior press release as corrected is set forth in its entirety below.

FL, July 26, 2022 - TRxADE HEALTH,

INC. (NASDAQ: MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail

pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., announced on July

25, 2022, its financial results for the 2022 second quarter (Q2) ended June 30, 2022.

Quarter 2022 and Subsequent Operational Highlights

continued to expand the TRxADE drug procurement marketplace nationwide, adding 319 new registered members in Q2 2022 and 685 new registered

members during the first six months of 2022, bringing the total registered members to approximately 13,815+ at June 30, 2022.

announced earlier this month that its wholly-owned pharmaceutical wholesale business Integra Pharma Solutions, LLC (d/b/a TRxADE Prime)

("Integra") secured a preferred distribution agreement with GALT Pharmaceuticals, LLC. Integra, which distributes generic

and brand medications directly in 34 states through its warehouse, has now added single-source and multi-source products directly from

GALT Pharmaceuticals, which further adds to the mission of helping independent pharmacies and its members access top medication products

as part of the TRxADE HEALTH network.

are pleased to have entered this partnership between Integra and GALT Pharmaceuticals, as it will diversify our product service offerings

and renew our commitment to the independent pharmacies we serve. In an everchanging healthcare landscape, equipping our pharmacies with

a robust catalog, creates value," said Mr. Suren Ajjarapu, Chairman and Chief Executive Officer of TRxADE.

Ajjarapu, commented, "2022 is an exciting time for TRxADE, as we continue to position ourselves to create sustainable value for

our stockholders. I am pleased with the growth we have experienced in our TRxADE and TRxADE Prime platforms. We continue to achieve several

key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities."

Quarter 2022 Financial Summary

for the second quarter of 2022, increased 73% to $3.3 million, compared to revenue of $1.9 million in the same quarter last year. The

increase in revenue was primarily due to revenue generated by the TRxADE Platform and TRxADE Prime.

profit increased to $1.2 million in the second quarter of 2022 compared to $0.8 million for the same period in 2021. As a percent of

revenue, gross profit decreased to 36% in the second quarter of 2022, as compared to 44% in the second quarter of 2021. The decrease

in gross profit was primarily attributable to higher costs associated with TRxADE Prime transactions.

expenses in the second quarter of 2022 were $2.3 million, compared to $3.4 million in the same quarter last year.

loss in the second quarter of 2022 was ($1.1) million, or ($0.13) per basic and diluted share outstanding, compared to a net loss of

($2.6) million, or ($0.32) per basic and diluted share outstanding, in the same quarter last year.

EBITDA, a non-GAAP financial measure was ($1.1) million for the second quarter of 2022, compared to ($1.2) million in the same quarter

last year. See "Use of Non-GAAP Financial Information" below, and the reconciliation of Adjusted EBITDA to GAAP set forth

at the end of this release.

metrics related to our key performance are as follows:

the six-month period ended June 30, 2022, the TRxADE Platform increased its registered users by 658. For the three-month period ended

June 2022, new registrations were 339 compared to 223 for the same period in 2021. Total registered users increased 8% to 13,816 from

12,762, as of June 30, 2022 and 2021, respectively.

table below summarizes the key metrics that management evaluated in relation to the activity on the TRxADE Platform for the three-month

period ended June 30, 2022 compared to the same period in 2021:

the three-month period ended June 30, 2022, compared to the same period in 2021, Integra Pharma Solutions, LLC ("TRxADE Prime")

increased processed sales volume over 430% and increased unique buyers on the TRxADE Prime platform by 130%.

table below summarizes the key metrics that management evaluated in relation to the activity for TRxADE Prime for the three-month period

ended June 30, 2022, compared to the same period in 2021:

will host a conference call on Monday, July 25, 2022, at 5:00 p.m. Eastern time to discuss TRxADE's second quarter 2022 financial

results. The call will conclude with Q&A from participants. To participate, please use the following information:

2022 Conference Call and Webcast

Monday, July 25, 2022

5:00 p.m. Eastern time

Dial-in: 1-877-425-9470

Dial-in: 1-201-389-0878

dial in at least 10 minutes before the start of the call to ensure timely participation.

playback of the call will be available through August 25, 2022. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671

when calling internationally and enter replay pin number 13731433. A webcast will also be available for 30 days on the IR section of

the Trxade Health website or by clicking the webcast link above.

HEALTH, Inc. (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug

procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace

serving a total of 13,815+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric

telehealth services and tele vet services. For more information on TRxADE Health, please visit the Company's IR website

at investors.trxadehealth.com.

of Non-GAAP Financial Information

addition to our results calculated under generally accepted accounting principles in the United States ("GAAP"), in this

earnings release, we also present EBITDA and Adjusted EBITDA which are "non-GAAP financial measures" presented as supplemental

measures of the Company's performance. They are not presented in accordance with GAAP. EBITDA represents net income (loss) attributable

to TRxADE HEALTH, Inc. before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before stock-based

compensation expense, litigation expenses, loss (gain) on inventory investment and loss (gain) on impairment of goodwill. EBITDA and

Adjusted EBITDA are presented because we believe they provide additional useful information to investors due to the various noncash items

during the period. EBITDA and Adjusted EBITDA are also frequently used by analysts, investors and other interested parties to evaluate

companies in our industry. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater

transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by

our institutional investors and the analyst community to help them analyze the health of our business. EBITDA and Adjusted EBITDA have

limitations as analytical tools, and you should not consider them in isolation, or as a substitute for analysis of our operating results

as reported under GAAP. Some of these limitations are: EBITDA and Adjusted EBITDA do not reflect cash expenditures, future requirements

for capital expenditures, or contractual commitments; EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for,

working capital needs; and EBITDA and Adjusted EBITDA do not reflect the significant interest expense, or the cash requirements necessary

to service interest or principal payments, on debt or cash income tax payments. Although depreciation and amortization are noncash charges,

the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect

any cash requirements for such replacements. Additionally, other companies in our industry may calculate EBITDA and Adjusted EBITDA differently

than TRxADE HEALTH, Inc. does, limiting its usefulness as a comparative measure. EBITDA and Adjusted EBITDA are not recognized in accordance

with GAAP, are unaudited, and have limitations as analytical tools, and you should not consider them in isolation, or as substitutes

for analysis of the Company's results as reported under GAAP. The Company's presentation of these measures should not be

construed as an inference that future results will be unaffected by unusual or nonrecurring items. We compensate for these limitations

by providing a reconciliation of each of these non-GAAP measures to the most comparable GAAP measure. We encourage investors and others

to review our business, results of operations, and financial information in their entirety, not to rely on any single financial measure,

and to view these non-GAAP measures in conjunction with the most directly comparable GAAP financial measure. For more information on

these non-GAAP financial measures, please see the section titled "Reconciliation of Net Income (Loss) attributable to TRxADE HEALTH,

INC., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA", included at the end of this

press release may contain forward-looking statements, including information about management's view of TRxADE's future expectations,

plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities

Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "may," "could,"

"expect," "intend," "plan," "seek," "anticipate," "believe,"

"estimate," "predict," "potential," "continue," "likely," "will,"

"would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are